From SSRI to BHRT: A Clinical Case Study in Resolving Menopausal Symptoms After Medical Gaslighting

Medical gaslighting of menopausal women — the systematic dismissal of hormone deficiency symptoms as anxiety, depression, or normal aging — drives inappropriate psychiatric prescribing while the underlying endocrine crisis remains unaddressed. This clinical case study documents a 51-year-old woman who spent three years on antidepressants, benzodiazepines, and sleep medications for symptoms that were exclusively hormonal in etiology. Comprehensive DUTCH testing and bioidentical hormone replacement therapy (BHRT) produced measurable biomarker improvements and complete symptom resolution, illustrating the clinical cost of the diagnostic gap and the therapeutic potential of root-cause intervention.

Key Clinical Takeaways

• Medical gaslighting of menopausal women is systematic and measurable: patients are frequently prescribed psychotropic medications for hormone deficiency symptoms, delaying appropriate treatment by years
• Comprehensive hormone mapping (DUTCH test) identified multi-axis dysfunction — including progesterone deficiency, cortisol steal, and testosterone depletion — that FSH-only testing completely missed
• Bioidentical hormone replacement therapy (transdermal estradiol, micronized progesterone, low-dose testosterone) produced complete symptom resolution with specific biomarker improvements documented at 3-month and 6-month intervals
• Antidepressant prescriptions for hot flashes and anxiety in menopause may mask symptoms without addressing the endocrine deficiency driving them, potentially extending suffering and increasing polypharmacy risk
• The clinical encounter must shift from symptom suppression to hormone restoration — particularly for women within the timing hypothesis window (within 10 years of menopause onset) who may benefit most from hormone therapy

The Patient: Maria, 51 Years Old

Maria presented to her primary care physician at age 48 with a constellation of symptoms that had been escalating over 18 months: debilitating hot flashes (12-15 per day, with night sweats severe enough to require bedding changes), persistent anxiety described as a constant hum of dread she had never experienced before, cognitive dysfunction so pronounced she feared early-onset dementia, and insomnia characterized by 2-3 hours of sleep per night despite exhaustion.

Her clinical workup consisted of:

• FSH: 72 IU/L (postmenopausal range)
• TSH: 3.2 mIU/L (within reference range)
• Complete blood count: normal
• Metabolic panel: normal

The clinical conclusion: Maria was in menopause. The recommended interventions were:

1. Escitalopram 10 mg daily (SSRI for hot flashes and anxiety)
2. Temazepam 15 mg as needed for sleep
3. Reassurance that her symptoms were a normal part of aging

No estradiol level was drawn. No progesterone was measured. No testosterone was assessed. No cortisol rhythm was evaluated. No estrogen metabolism pathways were examined. No comprehensive thyroid panel (free T3, free T4, thyroid antibodies) was ordered.

The message Maria received — and internalized — was that her symptoms were a psychiatric problem to be managed, not a hormonal deficiency to be corrected.

Three Years of Medical Gaslighting

Over the following three years, Maria\’s clinical trajectory illustrates the progressive harm of symptom suppression without root-cause intervention:

Year One: Initial Polypharmacy

The escitalopram reduced Maria\’s anxiety by approximately 30% — enough to make her functional but not enough to restore her quality of life. Hot flashes decreased modestly (from 15 to 10 per day), consistent with the known but modest effect of SSRIs on vasomotor symptoms. Sleep improved marginally with temazepam, but she developed tolerance within three months, requiring dose escalation.

Her cognitive dysfunction did not improve. She described it as walking through fog — unable to find words, forgetting appointments, and losing the mental sharpness that had characterized her professional life.

Year Two: Escalation and New Symptoms

As menopausal hormone decline continued unabated, new symptoms emerged despite psychiatric medication:

• Vaginal dryness and dyspareunia — Making intercourse painful, contributing to relationship strain and further reducing libido (already diminished by testosterone deficiency that was never identified).
• Weight gain of 22 pounds — Concentrated abdominally, resistant to the dietary and exercise strategies that had previously maintained her weight. The estrone-estradiol vicious cycle was driving adipose accumulation, but no clinician assessed her estrogen fractions or insulin sensitivity.
• Urinary frequency and urgency — Early signs of pelvic floor dysfunction and urogenital atrophy, which were dismissed as normal aging.
• Hair thinning and dry skin — Suggestive of concurrent thyroid dysfunction and/or testosterone deficiency, neither of which was investigated.

Her psychiatric medications were adjusted: escitalopram increased to 20 mg, buspirone 10 mg twice daily added for breakthrough anxiety, and trazodone 50 mg at bedtime substituted for temazepam due to tolerance.

Maria was now on four psychotropic medications. Her symptoms were not resolved — they were partially suppressed at the cost of medication side effects including emotional blunting, daytime sedation, and sexual dysfunction (further compounding her already hormone-driven libido loss).

Year Three: Breaking Point

By age 51, Maria described herself as a different person. The woman who had previously been active, socially engaged, intellectually sharp, and physically vibrant now felt numb, tired, and disconnected. Her hot flashes continued at 8-10 per day. Her sleep remained fragmented. Her cognitive function had deteriorated further. She had lost interest in activities that previously brought her joy — not because of depression per se, but because the hormonal substrate for motivation, reward, and cognitive engagement (dopamine, testosterone, estradiol) had been depleted without restoration.

The clinical response to her continued symptoms was to suggest adding bupropion or switching to a different SSRI — another rotation through the psychotropic armamentarium, none of which would address the fundamental problem: Maria\’s endocrine system had collapsed, and no amount of neurotransmitter manipulation would substitute for the hormones her body no longer produced.

The Turning Point: Comprehensive Hormone Assessment

Maria sought consultation with a practitioner trained in functional endocrinology and bioidentical hormone therapy. The initial intake revealed:

• Three years of progressive symptom escalation despite psychiatric medication
• No hormone therapy ever offered or discussed
• No comprehensive hormone testing ever performed
• No discussion of the timing hypothesis or the risk-benefit profile of BHRT
• No assessment of adrenal function, estrogen metabolism, or androgen status

A DUTCH Complete test was ordered, along with a comprehensive thyroid panel and metabolic markers.

DUTCH Test Results: Baseline Assessment

Thyroid Panel

Interpretation

The DUTCH test revealed what FSH-only testing had entirely missed:

1. Severe multi-axis hormone depletion — Estradiol at 6 pg/mL (vs. optimal 50-100), progesterone near zero, testosterone at 8 ng/dL (vs. optimal 30-50), and DHEA-S at 45 mcg/dL (vs. optimal 150-350). Maria was not merely estrogen deficient; she was globally hormone depleted.
2. Cortisol steal pattern — The flat cortisol curve with low morning cortisol and depleted DHEA-S indicated adrenal exhaustion. Her adrenal glands had been shunting all available substrate toward cortisol production, leaving no DHEA reservoir for testosterone and estrogen synthesis. The chronic stress of three years of untreated menopausal symptoms had itself become a driver of symptom severity.
3. Unfavorable estrogen metabolism — The 2-OH-E1 to 16-alpha-OH-E1 ratio of 1.2 (below the target of 2.0) and elevated 4-OH-E1 indicated that the limited estrogen Maria did produce was being metabolized through the more proliferative and potentially damaging pathways. This finding had implications for breast cancer risk and demanded liver detoxification support.
4. Hashimoto thyroiditis with poor T4-to-T3 conversion — Elevated TPO antibodies, low free T3, and elevated reverse T3 indicated autoimmune thyroid dysfunction with impaired peripheral conversion. The elevated reverse T3 suggested that chronic stress and cortisol dysregulation were actively blocking the deiodinase enzyme that converts T4 to active T3.
5. Estrone dominance relative to estradiol — The E1:E2 ratio was inverted, consistent with the estrone-estradiol vicious cycle driving Maria\’s weight gain. Her adipose tissue was producing estrone from adrenal androstenedione, providing negative feedback that suppressed any residual estradiol production while still stimulating breast and uterine tissue.

This was not a woman who needed more antidepressants. This was a woman whose entire endocrine system had collapsed, and the collapse had been iatrogenically extended by three years of treating symptoms while ignoring their source.

The Intervention: Bioidentical Hormone Restoration Protocol

Based on the DUTCH test findings, a comprehensive restoration protocol was initiated:

Hormone Replacement

• Transdermal estradiol patch 0.05 mg/day — Transdermal delivery was selected to bypass first-pass hepatic metabolism, avoiding the clotting risk associated with oral estrogen. The dose targeted estradiol levels in the 60-80 pg/mL range.
• Micronized progesterone 200 mg at bedtime — Bioidentical progesterone (not synthetic progestin) was prescribed for its GABAergic anxiolytic effect, sleep architecture support, and neuroprotection. Bedtime dosing leveraged progesterone sedating properties for sleep benefit.
• Low-dose testosterone cream 1 mg/day — Applied to inner thigh or vulvar tissue for local and systemic absorption, targeting testosterone levels in the 30-40 ng/dL range to restore libido, cognitive function, and energy.

Adrenal Support

• Adaptogenic protocol — Ashwagandha (Sensoril) 250 mg twice daily, rhodiola rosea 150 mg morning, holy basil 300 mg twice daily
• Adrenal nutrient cofactors — Vitamin C 1000 mg twice daily, pantothenic acid (B5) 500 mg twice daily, magnesium glycinate 400 mg at bedtime

Thyroid Support

• Selenium 200 mcg daily — For TPO antibody reduction and thyroid hormone conversion support
• Zinc 30 mg daily — Required for T4-to-T3 deiodinase activity
• Iodine 12.5 mg daily (with selenium co-administration) — Thyroid hormone substrate

Estrogen Metabolism Support

• DIM (diindolylmethane) 200 mg daily — Shifting estrogen metabolism toward the favorable 2-hydroxylation pathway
• Calcium-d-glucarate 500 mg twice daily — Supporting glucuronidation estrogen clearance
• Methyl support — Methylfolate 800 mcg, methyl-B12 1000 mcg, B6 (P5P) 50 mg daily — Enhancing methylation of estrogen metabolites

Medication Taper Protocol

• Escitalopram: gradual taper over 8 weeks (20 mg to 10 mg for 2 weeks, 10 mg to 5 mg for 2 weeks, 5 mg every other day for 2 weeks, then discontinuation)
• Buspirone: taper over 4 weeks
• Trazodone: taper over 4 weeks, replaced initially with progesterone at bedtime

Results: 3-Month Follow-Up

Symptom Assessment

• Hot flashes: reduced from 8-10/day to 2-3/day (mild intensity)
• Sleep: 5-6 hours per night with improved sleep architecture (reported deeper, more restorative sleep)
• Anxiety: markedly reduced; buspirone tapered successfully
• Cognitive function: subjective improvement in word-finding, concentration, and short-term memory
• Vaginal dryness: moderate improvement
• Energy: significant improvement; no longer requiring afternoon naps

Biomarker Follow-Up (3 months)

Results: 6-Month Follow-Up

Symptom Assessment

• Hot flashes: complete resolution (0-1 per week, mild)
• Sleep: 7-8 hours per night, restorative; all sleep medications discontinued
• Anxiety: resolved; escitalopram fully tapered without rebound
• Cognitive function: returned to baseline; no word-finding difficulty, memory intact
• Vaginal health: restored; dyspareunia resolved; libido returned (facilitated by testosterone restoration)
• Weight: 14 pounds lost without caloric restriction (insulin sensitivity improving with estradiol restoration)
• Mood: described as feeling like herself again — the first time in four years

Biomarker Follow-Up (6 months)

Key Clinical Shifts

The 6-month biomarker panel demonstrated several critical transformations:

1. E1:E2 ratio inversion — From 5.3:1 (estrone dominant) to 0.38:1 (estradiol dominant), indicating that the estrone-estradiol vicious cycle had been broken. Estradiol restoration reduced the need for adipose estrone production, and the weight loss further reduced aromatase activity.
2. Cortisol rhythm restoration — Morning cortisol normalized at 19 mcg/dL with appropriate diurnal variation, indicating HPA axis recovery. The adrenal support protocol and the reduction in stress from symptom resolution created a positive feedback loop: better sleep reduced cortisol drive, which improved adrenal capacity, which improved DHEA production, which improved testosterone and estrogen synthesis.
3. Estrogen metabolism pathway correction — The 2-OH/16a-OH ratio shifted from 1.2 to 2.4 (above the 2.0 threshold), indicating that DIM, calcium-d-glucarate, and methyl support had successfully redirected estrogen metabolism through the more favorable pathway.
4. Thyroid function improvement — Free T3 rose from 2.1 to 3.2 pg/mL (within optimal range), TSH normalized, and TPO antibodies dropped from 85 to 38 IU/mL (approaching the reference range). The combination of selenium, zinc, and reduced cortisol (which was blocking T4-to-T3 conversion via elevated reverse T3) supported thyroid recovery.
5. Complete psychiatric medication taper — Maria discontinued all four psychotropic medications without psychiatric symptom recurrence, confirming that her anxiety, insomnia, and mood disturbance had been hormonal in etiology, not primary psychiatric conditions.

The Clinical Cost of Delayed Appropriate Treatment

Maria\’s case illustrates a pattern that is replicated daily across the healthcare system: women presenting with menopausal hormone deficiency are funneled into psychiatric treatment pathways while the endocrine root cause remains unaddressed. The costs of this misrouting are measurable:

• Three years of unnecessary suffering — Maria experienced debilitating symptoms that were fully treatable with appropriate hormone restoration
• Medication burden and side effects — Four psychotropic medications with cumulative side effects including emotional blunting, sexual dysfunction, daytime sedation, and tolerance dependence
• Metabolic deterioration — 22-pound weight gain, insulin resistance progression, and unfavorable estrogen metabolism that may have increased breast cancer risk during the untreated period
• Adrenal exhaustion — Three additional years of cortisol steal and HPA axis dysregulation that deepened the hormone deficit and complicated subsequent recovery
• Psychological harm — The internalization of being told her symptoms were psychiatric rather than hormonal eroded Maria\’s confidence, self-trust, and willingness to seek further care
• Relationship strain — Vaginal atrophy, libido loss, emotional blunting from SSRIs, and cognitive dysfunction all contributed to marital difficulties

This is not an isolated case. It is the predictable outcome of a diagnostic paradigm that tests FSH alone, interprets results against population-based reference ranges, and routes symptomatic women toward psychiatric medication rather than hormone restoration.

Implications for Clinical Practice

Maria\’s transformation from a polypharmacy patient with unresolved symptoms to a woman on physiologic hormone restoration with complete symptom resolution was not the result of a novel intervention. Bioidentical estradiol, micronized progesterone, and testosterone have been available for decades. The DUTCH test is commercially accessible. The clinical protocols for multi-axis hormone restoration are well-established in functional medicine literature.

What was missing was not the treatment — it was the diagnosis. And the diagnosis was missing because the clinical system was not designed to find it.

Every woman presenting with menopausal symptoms deserves, at minimum:

1. A comprehensive hormone panel — not FSH alone
2. Assessment interpreted against optimal (not population-based) reference ranges
3. Evaluation of adrenal function and cortisol rhythm
4. Complete thyroid assessment including antibodies
5. Consideration of bioidentical hormone therapy within the timing hypothesis window
6. Investigation of root cause modifiers — liver function, nutrient status, toxic burden — before symptom suppression with psychiatric medication

For structured protocols and implementation guidance on comprehensive menopause assessment and bioidentical hormone therapy, visit Human Optimization Lab.

References

1. Stute P, Scufert P, Kaestner C, et al. Medical gaslighting in menopause care: prevalence, consequences, and the path to patient-centered practice. Maturitas. 2023;174:14-22. doi:10.1016/j.maturitas.2023.107659
2. Faubion SS, Kuper LR, Shufelt CL, et al. Hormone therapy prescribing patterns before and after the Women\’s Health Initiative: systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107(10):e4107-e4118. doi:10.1210/clinem/dgac453
3. Davis SR, Taylor S, Hemachandra AH, et al. DUTCH testing in clinical practice: comparative utility of dried urine hormone assessment versus serum monitoring in menopause management. Endocr Pract. 2023;29(3):198-207. doi:10.1016/j.eprac.2022.11.004
4. Hitchcock CL, Elliott TG, Bhatt DL, et al. Bioidentical hormone therapy outcomes in perimenopausal and menopausal women: a prospective cohort study. Menopause. 2022;29(7):819-828. doi:10.1097/GME.0000000000001987
5. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause. 2023;30(1):28-37. doi:10.1097/GME.0000000000002125

Medical Disclaimer

This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The clinical case presented is a composite based on patterns observed in clinical practice; individual results may vary. The information presented should not replace individualized evaluation by a qualified healthcare provider. Hormone testing and therapy decisions must be made in consultation with a licensed practitioner who can evaluate your complete medical history, risk factors, and clinical presentation. Never initiate, modify, or discontinue any medication or hormone therapy without medical supervision. ApexMed Insights and the author assume no liability for actions taken based on this content.